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Abstract 
 
Regulation of gene expression is one of several roles proposed for the stress-induced 
nucleotide diadenosine tetraphosphate (Ap4A).  We have examined this directly by a 
comparative RNA-Seq analysis of KBM-7 chronic myelogenous leukemia cells and KBM-7 
cells in which the NUDT2 Ap4A hydrolase gene had been disrupted (NuKO cells), causing a 
175-fold increase in intracellular Ap4A.  6,288 differentially expressed genes were identified 
with P < 0.05.  Of these, 980 were up-regulated and 705 down-regulated in NuKO cells with 
a fold-change ≥ 2. Ingenuity® Pathway Analysis (IPA®) was used to assign these genes to 
known canonical pathways and functional networks.  Pathways associated with interferon 
responses, pattern recognition receptors and inflammation scored highly in the down-
regulated set of genes while functions associated with MHC class II antigens were prominent 
among the up-regulated genes, which otherwise showed little organization into major 
functional gene sets.  Tryptophan catabolism was also strongly down-regulated as were 
numerous genes known to be involved in tumor promotion in other systems, with roles in the 
epithelial-mesenchymal transition, proliferation, invasion and metastasis.  Conversely, some 
pro-apoptotic genes were up-regulated.  Major upstream factors predicted by IPA
®
 for gene 
down-regulation included NFκB, STAT1/2, IRF3/4 and SP1 but no major factors controlling 
gene up-regulation were identified.  Potential mechanisms for gene regulation mediated by 
Ap4A and/or NUDT2 disruption include binding of Ap4A to the HINT1 co-repressor, 
autocrine activation of purinoceptors by Ap4A, chromatin remodeling, effects of NUDT2 loss 
on transcript stability, and inhibition of ATP-dependent regulatory factors such as protein 
kinases by Ap4A.  Existing evidence favors the last of these as the most probable mechanism.  
Regardless, our results suggest that the NUDT2 protein could be a novel cancer 
chemotherapeutic target, with its inhibition potentially exerting strong anti-tumor effects via 
multiple pathways involving metastasis, invasion, immunosuppression and apoptosis.   
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Introduction 
 
Nudix hydrolases regulate the levels of a wide variety of canonical and modified nucleotides 
and some non-nucleotide phosphorylated substrates as well as participating in essential 
processes such as mRNA decapping [1, 2].  One of the best studied is mammalian NUDT2.  
This enzyme has been isolated from many sources [3, 4] and its principal substrate is 
believed to be diadenosine 5′,5′′′-P1,P4-tetraphosphate (Ap4A).  In animal cells, Ap4A can be 
synthesized by most aminoacyl-tRNA synthetases, DNA ligases, firefly luciferase and acyl-
CoA synthetases while a further range of enzymes is able to do so in plants, fungi and 
bacteria [5-7]. Synthesis usually involves transfer of AMP from an acyl-AMP or enzyme-
AMP reaction intermediate to an ATP acceptor.  It can also be degraded by a number of 
enzymes in addition to NUDT2, including FHIT [8], aprataxin [9] and non-specific 
phosphodiesterases [3].  However, NUDT2 is believed to be principally responsible for 
maintaining the low level of intracellular Ap4A [10-12]. 
 
An increase in Ap4A resulting from activation of synthesis, inhibition of degradation or both 
has been implicated in several intracellular processes.  Genotoxic, thermal and other stresses 
lead to increased Ap4A [13-17] and so Ap4A has been implicated in the regulation of DNA 
replication after DNA damage and in promoting apoptosis [17-19].  Ap4A may also be raised 
in response to external ligands and act as an intracellular second messenger [20-22].  It also 
acts as an extracellular messenger through its interaction with a number of P2-type receptors 
[23].  Ap4A is also a ligand for a number of proteins including a multiprotein complex 
containing DNA polymerase-α [24, 25], protein kinases [26-28], uracil-DNA glycosylase 
[29], protein chaperones [30], the HINT1 tumor suppressor [31], 5′-nucleotidase II [32], CBS 
domain proteins [33, 34] and CFIm25 [35], but in most cases the significance of this binding 
is not clear.  Of particular interest, however, is the possibility that Ap4A may act as a 
transcriptional regulator. It has been suggested that an increased level of Ap4A induced in 
mast cells by external factors activates the expression of a subset of genes controlled by the 
MITF and USF2 transcription factors by binding to and displacing the inhibitory HINT1 
protein from these factors [10, 31, 36].   
 
In order to determine whether transcriptional regulation by Ap4A is confined to relatively few 
genes or is more widespread, we have analysed the transcriptome of a knockout derivative of 
the KBM-7 chronic myeloid leukaemia (CML) cell line [37] in which the intracellular level 
of Ap4A has been increased 175-fold by disruption of the NUDT2 gene (KBM-7-NuKO, 
referred to hereafter as NuKO).  These cells show profound changes in gene expression 
compared to the parent KBM-7 cell line with a total of 6288 significantly differentially 
expressed genes (DEGs) identified. Ingenuity
®
 Pathway Analysis was used to highlight the 
gene networks and metabolic and signaling pathways affected, revealing down-regulation of 
interferon, inflammatory and innate immune responses and up-regulation of processes 
involving MHC class II antigens.  In addition, many of the most strongly affected genes have 
roles in promoting cancer metastasis and invasion, suggesting that NUDT2 may offer a novel, 
multifaceted target for cancer chemotherapy. 
 
 
Materials and Methods 
 
Cells 
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The KBM-7 reference clone B (product no. P00174E07) and the KBM-7-NuKO derivative 
(P01289H04) in which the NUDT2 gene has been inactivated by retroviral gene-trap insertion 
[38] were obtained from Haplogen and maintained at 37
o
C in 5% (v/v) CO2/air in Isocoves 
modified Eagle medium (IMEM, Sigma) supplemented with 10% (v/v) Foetal Bovine Serum 
(Sigma), 2 mM L-glutamine (Sigma) and 100 µg mL 
-1
 penicillin-streptomycin (Sigma).   
 
Measurement of Ap4A and derivatives 
 
The level of intracellular Ap4A in log phase KBM-7 and NuKO cells was determined as 
previously described using a sensitive luminometric assay with slight modifications for use 
with suspension cells [17, 39].  Cells were harvested from suspension by centrifugation at 
500 g for 5 min and used for nucleotide extraction. Ap4A was also measured in the growth 
medium supernatant from these cells, which was filtered through a 0.2 µm Millipore filter, 
deproteinized with 10% TCA, then assayed as above.  ADP-ribosylated derivatives of Ap4A 
(ADPR-Ap4A) were separated by ion-exchange chromatography and identified and assayed 
as previously described [17]. 
 
Growth inhibition assays  
 
Cells (2 x 10
5
) were seeded into 25 cm
2
 flasks containing 7 mL of growth medium. Chemical 
agents were added as stated and cells grown for 96 h at 37
o
C after which cultures were 
centrifuged at 500 g for 5 min, cells resuspended in fresh medium, and counted using a 
haemocytometer. Average counts were normalized to the cell count of the untreated culture.  
 
 
RNA-Seq analysis: cDNA library preparation and sequencing 
 
Three independent samples of total RNA were prepared from both KBM-7 and NuKO cells.  
RNA extraction was performed using a Qiagen RNeasy mini kit with QIAshredder, and the 
quantity and quality determined using a Nanodrop and Agilent Bioanalyzer.  For each of the 
six samples, 10 µg of RNA was DNase-treated using an Ambion TURBO DNA-free kit 
and subsequently purified using AMPure XP beads. 2 µg of the DNase-treated total RNA 
was then subjected to rRNA depletion using the Ribo-Zero Gold (Human/Mouse/Rat) kit and 
purified again with Ampure XP beads. Successful depletion was assessed using a Qubit 
fluorometer and Agilent 2100 Bioanalyzer and all of the depleted RNA was used for the 
RNA-Seq library preparation using the ScriptSeq v2 protocol. Following 15 cycles of 
amplification the libraries were purified using Ampure XP beads. Each library was quantified 
using Qubit and the size distribution assessed using the Agilent 2100 Bioanalyzer. The final 
libraries were pooled in equimolar amounts using the Qubit and Bioanalyzer data. The 
quantity and quality of each pool was assessed with the Bioanalyzer and by qPCR using the 
KAPA Library Quantification kit for Illumina platforms on a Roche LC480II Light Cycler 
according to manufacturer's instructions. The template DNA was denatured according to the 
protocol described in the Illumina cBot user guide and loaded at a concentration of 9 pM. 
Sequencing was carried out on one lane of an Illumina HiSeq 2000 with version 3 chemistry 
generating 2  100 bp paired end reads.  Quality control was maintained with a 1% PhiX 
spike-in. 
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Bioinformatic analysis of RNA-Seq data  
 
Basecalling and de-multiplexing of indexed reads for each sample library was performed 
using CASAVA 1.8.2 (Illumina).  Raw fastq files were processed using Cutadapt 1.2.1 [40] 
with option “-O 3” set to remove adapter sequences of 3 bp or more.  Reads were further 
trimmed using Sickle 1.200 to remove low quality bases and finally reads <10 bp were 
removed.  The TopHat2 aligner version 2.0.10 [41] was used to align the trimmed R1-R2 
read pairs to the human reference genome assembly GRCh38, which contains 64,253 genes.  
Default parameters were used except for the library type option, which was set to “fr-
secondstrand” for all samples as the kit used produced a second-strand library type (R1 is 
expected to map on the 5′→3′ strand and R2 on the 3′→5′ strand).  Reads aligning to the 
reference in more than one position were discarded and FKPM values (fragments per 
kilobase transcript per million reads mapped) calculated. Differential gene expression 
analysis was conducted in the R environment using the edgeR package [42].  The count data 
were normalised across libraries using the Trimmed Mean M-values (TMM) method in 
edgeR with default parameters.  Tagwise dispersion parameters were estimated and then used 
for log2FC (log2 Fold Change) estimation and testing in edgeR using the Likelihood Ratio 
(LR test) [43]. P values associated with log2FC were adjusted for multiple testing using the 
False Discovery Rate (FDR) approach [44]. Significant DEGs were defined as those with an 
FDR-adjusted P value < 0.05.  All original RNA-Seq data produced in this study have been 
submitted to the EMBL-EBI ArrayExpress database under accession number E-MTAB-4104. 
 
 
RT-PCR analysis of selected genes 
 
RNA extraction was performed using a Qiagen RNeasy mini kit with QIAshredder and 
cDNA was synthesized using a Bioline Tetro cDNA synthesis kit, both according to the 
manufacturer’s instructions. The cDNA was then quantitated by PCR using Maxima SYBR 
Green master mix (Thermo) and a StepOnePlus™ Real Time PCR system (Applied 
Biosystems).  Primers were obtained from Sigma and are listed in S1 Table.  The 2
-ΔΔCt
 
method was used to determine relative transcript levels using the housekeeping GAPDH gene 
to normalize the data [45].   
 
 
Pathway analysis 
 
Genes showing ≥ 2-fold up- or down-regulation with an FDR-adjusted P value < 0.05 were 
analyzed through the use of QIAGEN Ingenuity
®
 Pathway Analysis software (IPA
®
, 
QIAGEN, Redwood City, http://www.ingenuity.com) in order to assign them to different 
functional networks.  IPA
®
 uses the manually curated Ingenuity® Knowledge Base, which 
contains information from several gene and protein expression, interaction and annotation 
databases such as IntACT, BIND and MiPs, as well as from the published literature [46].  We 
also used IPA to identify functionally related genes that correspond to specific canonical 
pathways that were most significant to the data set from a collection of 200 curated metabolic, 
cell-signaling cascade and disease-associated pathways. Fisher’s exact test of independence 
was used to calculate the probability that the association between the genes in the dataset and 
the canonical pathway can be explained by chance alone. Finally, we used the IPA upstream 
regulator analysis to identify factors that may control the genes and pathways highlighted by 
network analysis to provide testable hypotheses for gene regulation by Ap4A. 
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Results 
 
Level of Ap4A in KBM-7-NuKO cells 
 
The parent KBM-7 line used in this study contains the BCR-ABL1 gene fusion and potentially 
inactivating mutations in TP53 and NOTCH1, but lacks the other common genetic aberrations 
found in myeloid malignancies [38]. It expresses the majority of annotated proteins from a 
wide range of signaling pathways, making it a suitable cell line for this study. The complete 
absence of NUDT2 protein from the NuKO NUDT2 disruptant was confirmed by Western 
blotting (Fig. 1). The steady-state concentration of intracellular Ap4A in unstressed 
mammalian cells is typically in the range 0.1-1.0 pmol/10
6
 cells (0.05-0.5 µM), the exact 
amount being species- and cell type-dependent [17, 47].  Log phase KBM-7 cells had a level 
of 0.21±0.02 (n=3) pmol/10
6
 cells.  However, the NuKO derivative had a 175-fold increased 
level of 36.9±0.3 (n=3) pmol/10
6
 cells, providing the clearest evidence yet that Ap4A is an 
important NUDT2 substrate in vivo and that this enzyme plays an essential role in 
maintaining the low background level of Ap4A.  Note that an Ap4A content of 1 pmol/10
6
 
cells equates roughly to an intracellular concentration of 0.5 µM if uniformly distributed [17] 
so the level in NuKO cells will be around 20 µM.  Regarding whether this high level and the 
resulting changes in the cells reported here are biologically relevant, we have previously 
measured up to 20 µM Ap4A in DNA repair-defective cells treated with mitomycin C [17] 
while a concentration as high as 775 µM has been reported in FCεR1-activated mast cells 
[31].  Chromatographic analysis of the Ap4A from NuKO cells showed that about 35% was 
present in the form of ADP-ribosylated derivatives (ADPR-Ap4A), mainly mono-ADPR-
Ap4A (Fig. 1).  We have previously shown that ADP-ribosylation of Ap4A by PARP1 and 
PARP2 in Chinese hamster EM9 cells and mouse embryo fibroblasts occurs in response to 
DNA damage [17]; however, it appears that the high level of Ap4A here is subject to 
constitutive ADP-ribosylation. 
 
 
RNA-Seq and differential gene expression analysis 
 
Ap4A has been reported to activate the transcription of subsets of genes controlled by the 
transcription factors MITF and USF2 [31, 36].  In view of this, and to further explore the 
phenotype of the NUDT2 knockout cells, we carried out a comparative analysis of the 
transcriptomes of KBM-7 and NuKO cells by RNA-Seq to identify DEGs.  An average of 
46.1 million pairs of 100 bp paired-end reads per sample were generated that aligned to the 
reference human genome.  Alignment results are summarized in Table 1, showing the number 
and percentage of reads mapped for each sample.  Mapping percentages for the six samples 
were between 80.2 and 81.3%. 31,177 (48.5%) of the 64,253 reference genes had at least one 
read aligned while 33,076 genes had no read aligned from any of the six samples.   
 
The difference in gene expression profiles between the two cell types is illustrated in the 
Principal Component Analysis (PCA) plot of log2 gene expression data shown in Fig.2A. The 
triplicate samples of each cell type are grouped well away from each other, indicating a high 
degree of differential gene expression between them.  Furthermore, the heatmap of the 
Pearson correlation coefficients in Fig. 2B indicated that the expression profiles for the three 
samples from the same cell type were much more closely correlated than samples from 
different cell types, showing that the effect of NUDT2 knockout on gene expression was 
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much stronger than the influence of any technical or biological variations between samples. 
The heatmap also shows a very high correlation (R >0.99) among samples from the same cell 
type. Thus, we can conclude that the differential gene expression detected here is statistically 
very robust.       
 
Of the 31,177 reads mapped (S2 Table) a total of 6,288 DEGs were identified with a P-value 
(FDR-adjusted) < 0.05, of which 2,550 were up-regulated and 2,285 down-regulated with a 
fold-change ≥ 1.2 (Fig. 2C and S3 Table).  The MA plot in Fig. 2C shows a fairly 
symmetrical distribution of up- and down-regulated genes at all levels of expression.  Of 
these genes, 980 were up-regulated and 705 down-regulated with a fold-change ≥ 2. In both 
cases, 88% had FPKM ≥ 0.3 for one or both of the WT and KO datasets. The 40 most 
strongly down- and up-regulated annotated genes are shown in Tables 2 and 3 respectively.  
Note that many of these genes had zero read counts for either the WT or KO datasets 
necessitating the addition of a small zero-offset pseudocount by the edgeR software in order 
to calculate log2FC [42].   
 
The RNA-Seq analysis was validated by performing real-time qRT-PCR on a selection of 
genes representing various affected pathways (Fig. 3). These results confirmed the direction 
of regulation (up or down) for all genes studied.  The magnitude of change was also similar 
for the majority of genes, with a correlation coefficient of 0.83 between the two data sets (Fig. 
3, inset).  However, for some genes with a zero value of FPKM for one of the samples in the 
RNA-Seq analysis, the use of the pseudocount method by edgeR to calculate a fold-change 
has led to a significantly different value, e.g. GFRA1 and TNF.  Nevertheless, the values 
calculated by edgeR are used in the following discussions as they are available for all genes 
and are still a good relative indication of the change in expression.  In order to show that the 
observed differential gene expression correlates solely with increased Ap4A rather than the 
related ADPR-Ap4A derivatives, qRT-PCR analysis was also performed with RNA extracted 
from NuKO cells grown in the presence of 100 nM KU-0058948, a PARP1 and PARP2 
inhibitor that prevents the synthesis of ADPR-Ap4A species [17].  The results were very 
similar to those obtained in the absence of KU-0058948 (Fig. 3), showing that, for these 
genes at least, ADPR-Ap4A is not the cause of the differential expression.  The function of 
ADPR-Ap4A, if any, is still unclear. 
 
Ingenuity
®
 Pathway Analysis 
 
In order to place the gene expression data into a biological context, Ingenuity
®
 Pathway 
Analysis (IPA
®
) software was used to assign the DEGs to known canonical pathways and 
functional networks in order to predict the biological functions of the transcriptional changes. 
For simplicity, the initial analysis included only genes that were up- or down-regulated by ≥ 
2-fold (P < 0.05); however, where present in the resulting pathways and networks, genes up- 
or down-regulated by ≥ 1.2 were also considered to be of potential interest as there is no 
biological justification for a cut-off value of 2.  It was found that the DEGs mapped to a large 
number of pathways with a significant enrichment score (–log(P-value)) (S4 Table).  Top 
ranked within both up- and down-regulated gene sets were signaling pathways related to 
immunity and inflammation.  Pathways associated primarily with the innate immune 
response, such as activation of interferon regulatory factors (IRFs) by pattern recognition 
receptors (PRRs), and inflammation were specifically enriched in the down-regulated set of 
genes while functions associated with MHC class II antigens were specific for the set of up-
regulated genes (Table 4).  The predominance of these pathways in the dataset may reflect 
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the myeloid nature of the KBM-7 cell line [37].  These pathways are discussed in detail 
below. 
 
Interferon response and innate immunity 
 
Interferons are important mediators of the innate immune response, which provides an initial 
vital defence against invading pathogens (viruses, bacteria, protozoa) following interaction of 
pathogen components with PRRs in various cellular compartments. They can also inhibit cell 
proliferation, modulate the adaptive immune response, and be pro- or anti-inflammatory, 
depending on context [48-51].  Submission of the set of 4,835 DEGs with fold change ≥ 1.2 
to the Interferome database (v2.01) [52] revealed a subset of at least 1,038 DEGs known to 
be regulated by Type I IFNs (IFNα and IFNβ) in other systems.  Roughly half of these 
overlapped with the set of 944 showing known regulation by Type II IFNs (IFNγ). Some (56) 
also showed Type III (IFNλ) regulation with 15 of these potentially unique to Type III (S5 
Table). 
 
Fig. 4 shows the IPA
®
 canonical pathway for activation of interferon receptors (IFNRs) by 
Type I and Type II interferons, with examples of genes found to be differentially expressed in 
this study highlighted.  The majority of functions in this pathway were down-regulated, with 
expression of IFNB being the most strongly affected (15-fold, S3 Table).  The JAK-STAT 
signaling pathways are central to the interferon response.  In Type II interferon signaling, 
activated STAT1 homodimers bind to the GAS (Interferon Gamma Activated Sequence) 
promoter and induce gene expression while Type I signaling involves the combination of 
STAT1-STAT2 heterodimers with IRF9 (Interferon Response Factor 9) forming ISGF3 
(Interferon Stimulated Gene Factor), which then binds to the ISRE (Interferon-Stimulated 
Response Element) promoter. STAT1, STAT2 and IRF9 were all down-regulated (1.4-, 1.8- 
and 3.7-fold respectively) while the pathway suppressors SOCS1 and PTPN2 were up-
regulated (1.2-1.4-fold).  Though individually slight, the combined effect of these changes 
could nevertheless be significant.  The increases in SOCS1 and PTPN2 also show that there is 
not just a general suppression of gene expression but that negative feedback via these genes is 
preserved.  Finally, several of the STAT-controlled genes that are down-regulated are 
themselves activators of further IFN response genes, e.g. IRF1, IRF7 and IRF9 (1.2-, 3.8- and 
3.7-fold respectively). 
 
The canonical pathway in Fig. 5 highlights the roles of the three RIG-1-like helicase PRRs of 
the innate immune response, RIG-1 (DDX58), MDA5 (IFIH1) and LGP2 (DHX58) in the 
activation of IFNB following stimulation by viral double-stranded RNAs and the feedback 
provided by IFNβ on the expression of these PRRs.  All three receptor genes are down-
regulated (3.1-, 2.3- and 3.0-fold respectively) (S3 Table) in NuKO cells.  In addition, 
IFITM2 and IFITM3, whose products restrict the entry of many viruses [53], and all four 
antiviral IFIT family members that bind viral components (IFIT1, 2, 3 and 5) [54] are down-
regulated between 1.6- and 6.8-fold.  Other down-regulated anti-viral genes include PKR, 
GBP1 and TLR10 [55-58] (S3 Table). 
 
Cytokine signaling, inflammation and NF-κB 
 
Interleukin-1 (IL-1) signaling is flagged by IPA
®
 as a top down-regulated pathway (Table 4) 
with reduced expression of important pro-inflammatory members of the IL-1 superfamily 
[59].  For example, the mRNAs for IL-1β, its receptor IL-1R1 and accessory protein IL-
1RAP are decreased 1.5-, 11.7- and 1.2-fold respectively while IL-18, IL-18R1 and IL-
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18RAP are down 2.3-, 3.0- and 4.0-fold respectively.   Expression of pro-inflammatory IL32 
is also reduced 5-fold, while the expression of Tumor Necrosis Factor (TNF or TNFα), which 
can activate both Type I IFNs and the inflammatory mediator NF-κB, is down-regulated 30-
fold (S3 Table).  The canonical pathway leading to transcriptional activation by NF-κB 
through IL-1, TNFα and other ligands is shown in Fig. 6.  The NF-κB complex is an 
important mediator of inflammatory and immune responses and responds to PRRs and pro-
inflammatory cytokines [60]. It can synergize with STAT signaling with the increased 
induction of target genes resulting from coordinate binding of STATs and NF-κB to GAS and 
NF-κB promoters.  The p50 and p52 components of the NF-κB complex and the RELB 
transactivator are all down-regulated as are many components of signaling pathways that lead 
to NF-κB activation.  
 
It is known that Type I IFNs and TNF can mutually suppress each other’s expression, and it 
has been suggested that changes in the cross-regulation of these pathways might affect the 
balance between the potential destructive and protective roles of these cytokines in the 
pathogenesis of autoimmune inflammatory diseases such as systemic lupus erythematosus 
(SLE) and rheumatoid arthritis (RA) [61]. IPA
®
 identifies signaling in RA as a top-ranked 
affected canonical pathway (Table 4) and the list of DEGs associated with RA and SLE are 
shown in S6 Table.  Although the modest changes in expression in some other cytokine 
receptors could potentially be pro-inflammatory (e.g. IL10RA and IL23R), the overall picture 
is one of the suppression of inflammation by elevated Ap4A, with the down-regulation of NF-
κB signaling featuring strongly.   
 
Up-regulated canonical pathways and MHC class II antigens 
 
KBM-7 cells can be regarded as immature precursors to professional antigen-presenting cells 
such as macrophages and dendritic cells and almost all of the top 20 up-regulated canonical 
pathways flagged by IPA
®
 involve functions associated with the adaptive immune response, 
including antigen presentation, OX40 signaling, allograft rejection and B cell development 
(Table 4 and S4 Table).  However, it should be emphasized that this is largely because these 
pathways all involve one of the most prominent up-regulated gene sets, the inducible MHC 
class II antigens (MHC-II). MHC-II molecules are mainly concerned with the presentation of 
antigens derived from extracellular pathogens resulting in CD4+ T helper cell priming and 
the production of antibodies by B cells [62].  Almost all class II subtype genes show a 
significant increase in expression, with some showing a large increase, e.g. HLA-DOA 47-
fold and HLA-DPA1 12-fold.  Thus, the extent to which these canonical pathways can be 
regarded as up-regulated as a whole is open to question.   
 
Nevertheless, in addition to MHC-II, a number of other genes involved in promotion of 
aspects of the adaptive immune response are up-regulated in NuKO cells.  OX40 (CD134, 
TNFRSF4) is a member of the TNF receptor superfamily expressed by activated T helper 
cells and other cells and when engaged by the OX40L ligand promotes the clonal expansion 
of effector and memory T cells responding to an antigen [63].   It is up-regulated 5-fold.  
CD86 (up 2.2-fold) is expressed on antigen-presenting cells and interacts with T cell surface 
ligands.  It is crucial for effective T cell activation and survival [64] and several studies have 
shown that down-regulation or blockade of CD86 can improve allograft survival [65].  
FCER1G (up 8-fold) encodes the γ chain (FcRγ) of the high affinity IgE receptor FCεR1 [66].  
FcRγ is also a component of several other Fc receptors and the T-cell receptor, which may 
explain its association by IPA
®
 with several immune functions.  Interestingly, activation of 
mast cells by aggregation of FCεR1 with IgE-antigen complexes has been reported to 
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promote synthesis of Ap4A by lysyl-tRNA synthetase and the consequent transcriptional 
changes [10, 31, 36].  Up-regulation of FCER1G might therefore provide a mechanism to 
potentiate and prolong Ap4A synthesis.  
 
Together, these data suggest reinforcement of elements of the adaptive immune response by 
elevated Ap4A.  As far as KBM-7 cells are concerned, this may indicate that Ap4A is 
promoting their differentiation from a blast-like phenotype to a more mature stage [67].  
There are some apparent exceptions, such as the down-regulation of the recombination 
activating genes RAG1 and RAG2 (down 4.4- and 107-fold respectively).  The RAG proteins 
catalyze VDJ recombination and are essential for the generation of mature, functional T and 
B cells [68].  These genes are moderately expressed in KBM-7 cells and can be highly 
expressed in other blast-phase CML-derived cell lines, e.g. NALM-1 [69].  However, their 
relevance to immune function is in lymphocytes, in which their expression is normally 
confined, and in that context they may not be down-regulated by high Ap4A. 
 
Tryptophan catabolism 
 
Canonical pathway analysis also shows that a number of metabolic pathways including 
tryptophan (Trp) catabolism, and consequently de novo NAD+ biosynthesis (derived from 
Trp [70]), are strongly associated with the set of down-regulated genes (Fig. 7 and S4 Table) 
while creatine phosphate biosynthesis, melatonin degradation (also a Trp derivative) and 
NAD+ phosphorylation are associated with the set of up-regulated genes. The strong down-
regulation of both major pathways of Trp catabolism, particularly the key enzymes 
kynureninase (KYNU, 65-fold), indoleamine 2,3-dioxygenase (IDO1, 19-fold) and DOPA 
decarboxylase (Trp decarboxylase, DDC, 16-fold) is of particular note. Expression of the 
rate-limiting IDO1 is induced in myeloid-lineage cells by IFNs, particularly Type II, and 
TNF can act synergistically to increase IDO1 expression [71], so the observed down-
regulation of these pathways in NuKO cells combined with the moderate up-regulation of the 
negative effectors DAP12 (TYROBP) and BIN1, a tumor suppressor, (S3 Table) [72] would 
be expected to reduce IDO1 expression substantially.   
 
There is strong evidence that Trp catabolism and IDO1 expression in dendritic cells, which 
have a myeloid lineage, are important for the suppression of T-cell responses and the 
promotion of immune tolerance [73].  The reduction of extracellular Trp, the generation of 
metabolites via the kynurenine pathway and the signaling function of tyrosine-
phosphorylated IDO1 all contribute to immunosuppression and protection against 
autoimmune disease and allograft rejection by inhibiting the proliferation of T cells and NK 
cells and promoting autophagy and anergy [74, 75].  The strong down-regulation of Trp 
catabolism caused by elevated Ap4A would therefore be expected to promote T-cell 
responses and suppress tolerance.  This is consistent with the up-regulation of adaptive 
immune functions in NuKO cells predicted by IPA
®
 (Table 4).  Furthermore, overexpression 
of IMPACT, an inhibitor of the GCN2-kinase (EIF2AK4) stress-signaling pathway that 
represses translation and proliferation in response to amino acid starvation, protects T-cells 
from Trp depletion [76].  IMPACT is up-regulated 13-fold in NuKO cells (S3 Table) and this 
would contribute further to the promotion of T-cell responses if reproduced in T cells.   
 
Cancer 
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Introduction of Ap4A by cold shock into some cell lines has been reported to induce cell 
cycle arrest and apoptosis [19, 77].  It has also been shown that the level of NUDT2 
expression positively correlates with lower survival and increased lymph node metastases in 
breast carcinoma [78].  This suggests that low Ap4A might promote and/or high Ap4A might 
inhibit cancer progression.  Given the multifactorial nature of the disease, it is not surprising 
that IPA
®
 classifies 1,108 of the 1,685 DEGs with ≥ 2-fold change and P ≤ 0.05 as being 
increased, decreased or affected (usually by mutation association) in cancer.  So, to 
investigate further whether the level of Ap4A might correlate with cancer cell proliferation, 
survival or metastasis, we have further filtered this DEG set to exclude those with FPKM 
values < 0.3 for both WT and KO samples to focus attention on the more abundant transcripts 
and avoid any uncertainties about the biological impact of DEGs with low level expression. 
We then conducted a literature search on the 40 most strongly up-regulated and down-
regulated annotated protein-coding genes satisfying these conditions (S7 Table).  Existing 
experimental evidence suggests that reduced expression of 14 of the top 40 down-regulated 
genes would lead to a significant anti-cancer effect while reduced expression of only 2 might 
have a promotional effect.  A further 3 could be pro- or anti-cancer depending on cellular 
context.  Of the top 40 up-regulated genes, increased expression of 8 restricts cancer 
progression in other systems, while only 2 promote it and one could possibly do either (S7 
Table).  Thus, increased intracellular Ap4A seems to be associated overall with a strong anti-
cancer effect. A more detailed appraisal of these genes follows.  It is worth noting that the 
well-characterized FHIT tumor suppressor protein that binds both Ap3A and Ap4A [8, 79] is 
not expressed in KBM-7 cells, probably as a result of gene deletion [38]. 
 
Several genes showing a high degree of differential expression have been associated in other 
cell systems with the epithelial-mesenchymal transition (EMT) — the loss of cell-cell 
adhesion that initiates metastasis — and the reverse process, mesenchymal-epithelial 
transition (MET), which stabilizes and integrates the cancer cells into tissues: 
 
(i) GFRA1 encodes a receptor for glial cell line-derived neurotrophic factor (GDNF) and is 
classified by edgeR as the most strongly down-regulated gene in the dataset (3221-fold). 
The proliferation of prostate cancer cells and their resistance to genotoxic treatment 
correlate directly with the level of GFRA1 expression [80].  It is also up-regulated in 
breast carcinoma [81] while GFRA1 released by cells can promote cancer cell 
migration and invasion [82]. 
(ii) Expression of the transcription factors OVOL1 and OVOL2 in mesenchymal prostate 
cancer and poorly differentiated breast cancer cells induces MET and so inhibits their 
metastatic potential [83]. It has been proposed that the EMT/MET balance is regulated 
by the ratio of OVOL1/2 (promote MET) to ZEB1/2 (promote EMT) expression.  
OVOL1 is up-regulated 719-fold in NuKO cells (although OVOL2 expression is 
decreased 8-fold) while ZEB1 and ZEB2 are slightly down 1.4- and 1.2-fold 
respectively.   
(iii) The secreted glycoprotein EDIL3 has recently been identified as a novel inducer of 
EMT in hepatocellular carcinoma.  It promotes cell migration, invasion and 
angiogenesis [84].  It is also up-regulated in oral squamous cell carcinoma [85] but is 
down-regulated 590-fold in NuKO cells.   
(iv) The mRNA binding protein IGF2BP1 promotes EMT while its knockdown reduces cell 
migration in various mesenchymal-like tumor cells [86].  It is down 122-fold.   
(v) GJA-1 was recently characterized as a key gene for cervical cancer invasion and 
metastasis [87] and is down 120-fold in NuKO cells.  
(vi) The transmembrane protein TM4SF1 is overexpressed in many cancers and in the 
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tumor vascular endothelium [88] with its level correlating with poor prognosis in 
glioblastoma [89].  Its down-regulation by an endogenous miRNA in prostate cancer 
cells inhibited migration and invasion [90].  It is down 70-fold. 
(vii) BRINP3 overexpression in pituitary gonadotrope cells promotes proliferation, 
migration, and invasion [91].  It is down 136-fold. 
(viii) MPZL2 expression is significantly decreased in breast carcinoma cells growth-arrested 
by siRNA knockdown of the migration and invasion regulatory PACE4 proprotein 
convertase [92].  Its expression is reduced 260-fold in NuKO cells.   
(ix) The RAC1-activating guanine nucleotide exchange factor PREX2, which is frequently 
mutated in cancer and which promotes migration and invasion of various neoplasias [93, 
94] is down 44-fold. 
(x) High expression of the HSP40 family member DNAJC12 has been found to correlate 
with colorectal tumor progression and invasion and with a poor response to 
neoadjuvant concurrent chemoradiotherapy [95].  It is down-regulated 41-fold in 
NuKO cells. 
(xi) Down-regulation of the transcription factor FOXD3 promotes an EMT phenotype in 
breast cancer cells, causing proliferation and invasion both in vivo and in vitro while 
overexpression inhibits this phenotype [96, 97].  Similar results have been found with 
other cancers [98, 99].  It is up-regulated 16-fold in NuKO cells. 
(xii) Overexpression of NKD2, a negative regulator of Wnt signaling, in metastatic 
osteosarcoma and breast carcinoma significantly reduces tumor growth and metastasis 
in vivo and decreases cell proliferation, migration and invasion in vitro, while down-
regulation has the opposite effect [100, 101].  It is up-regulated 19-fold. 
(xiii) The leukemia inhibitory factor receptor LIFR has been shown to act as a suppressor of 
metastasis in hepatocellular carcinoma [102].  Increased LIFR activity has also been 
correlated with a reduction in the pool of breast cancer stem cells [103].  It is up-
regulated 11-fold. 
 
Several other prominent DEGs are known to affect growth and apoptosis in other systems.  
The Wilms’ tumor transcriptional regulator WT1 can exhibit both oncogenic and tumor 
suppressor activities depending on its association with specific co-regulators [104, 105].  For 
example, the co-repressor BASP1 interacts with WT1 in a complex with PHB and BRG1 to 
favor growth arrest and the induction of apoptosis over proliferation [106].  All these genes 
are well expressed in KBM-7 cells, with BASP1 exhibiting 35-fold up-regulation in NuKO 
cells.  Up-regulation of IFI44L is associated with melanoma and prostate cancer [107, 108] 
while overexpression of NKX2-2 is associated with Ewing’s sarcoma and fibromatosis [109].  
They are down 224- and 125-fold respectively in NuKO cells.  The homeobox transcription 
factor NKX3-1 is a prostate tumor suppressor [110] and its expression is increased 13-fold in 
NuKO cells.  Overexpression of the coiled coil domain protein CCDC68 decreased 
proliferation and tumorigenicity of pancreatic ductal adenocarcinoma cells while allelic loss 
was found in about half the tumors examined [111].  It has also been identified as a possible 
tumor suppressor in colorectal cancer [112] and is up-regulated 11-fold in NuKO cells.  Even 
genes with a more modest change in expression could have a profound anti-cancer effect; for 
example, Interferon Regulatory Factor 4 (IRF4), an important NF-κB-activated regulator of 
immune system development and the innate immune response [113], also plays an essential 
role in many lymphoid malignancies, and knockdown of its expression by only 50% is lethal 
to multiple myeloma cells [114, 115].  It is down-regulated 7-fold in NuKO cells. 
 
Mixed results have been reported for a few of these DEGs in other contexts.  For example, 
high expression of the cysteine-rich secretory protein CRISP3 (down 130-fold in NuKO 
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cells) has been found in certain subtypes of prostate cancer [116] but down-regulation has 
been associated with oral squamous cell carcinoma [117].  A similar pattern has been found 
for the JCHAIN component of IgA and IgM (down 75-fold), which is up-regulated in 
prostate [108] but down-regulated in colorectal cancer [118].  The chemokine CXCL10 is 
another factor with both tumor-promoting and anti-tumor effects, the latter largely through its 
immunogenic action.  It is overexpressed up to 40-fold in most types of cancer and can 
promote tumor cell growth and metastasis [119] but is down 66-fold in NuKO cells.  Mixed 
results have also been reported for the Ig superfamily protein CD200 and the transmembrane 
co-receptor syndecan-4 (SDC4), with both pro- and anti-cancer roles suggested in different 
situations [120-122].  They are down 51- and up 35-fold in NuKO cells respectively. 
 
The change in expression of a small number of genes in NuKO cells could potentially 
promote cancer.  For example, reduced expression of early B-cell factor 1 (EBF1) has been 
found in Hodgkin lymphoma and appears to contribute to the loss of B-cell phenotype and 
consequent malignancy [123].  There is also evidence for a tumor suppressor role in mouse 
leukemia [124].  It is down-regulated 38-fold.  Expression of the TNF family member CD70 
is normally restricted to activated T and B-cells but it is activated in a wide variety of tumors 
where it promotes tumor cell expansion and survival [125]. It is up-regulated 17-fold.  Finally, 
type II transglutaminase (TGM2) is up-regulated 10-fold in NuKO cells and may have an 
important role in maintaining survival, invasion and the metastatic behavior of a variety of 
tumors and cancer stem cells [126] while sphingosine-1-phosphate phosphatase 2 (SGPP2, up 
63-fold) may be a target for the tumor suppressor miRNA-31 [127]. 
 
If the above set of prominent DEGs were expressed and responded in the same way to 
increased Ap4A in carcinomas, the overwhelming net effect could be the strong suppression 
of tumor growth and, particularly, metastasis. Furthermore, as indicated previously, IDO1 
and several other enzymes of Trp catabolism are strongly down-regulated in NuKO cells.  
Increased IDO1 expression is a characteristic of many cancer cells and assists them in 
avoiding clearance by the immune system, with the level of expression often correlating with 
poor prognosis [72, 128] and so inhibitors of IDO1 have been considered as novel 
immunotherapeutic adjuvants to conventional anti-cancer drugs [129, 130].   
 
Taken together, there seems to be sufficient evidence to support NUDT2 as a novel 
chemotherapeutic target that could conceivably exert an anti-cancer effect via multiple 
pathways involving apoptosis, metastasis, invasion and immunosuppression.  One additional 
benefit of targeting NUDT2 could be the 158-fold down-regulation of O
6
-methylguanine-
DNA methyltransferase (MGMT).  The MGMT protein dealkylates toxic and mutagenic O
6
-
alkylguanine lesions in DNA exposed to alkylating agents [131] and its reduced expression in 
NuKO cells renders them much more sensitive to growth inhibition by methylmethane 
sulfonate (MMS), N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) and N-methylnitrosourea 
(MNU) (Fig. 8).  While down-regulation by high Ap4A would in theory promote the 
carcinogenic effect of environmental alkylating agents, it would also render cancer cells more 
sensitive to alkylation therapies such as temozolomide, a common treatment for glioblastoma 
and astrocytoma.  MGMT status is an important determinant of the success of these therapies 
[132].  This sensitivity to methylating agents also provides good phenotypic confirmation of 
the transcriptomic data. 
 
IPA
® 
prediction of upstream regulatory factors 
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IPA
®
 prediction of key upstream regulators for the DEGs suggests numerous factors 
controlling large sets of down-regulated genes with fewer factors controlling small groups of 
up-regulated genes.  Of the top 100 most significant potential regulators, 97 are proposed to  
contribute to gene down-regulation (S8 Table) although the total number of genes that are up- 
and down-regulated is similar. The inter-relationships between the top-ranked transcription 
factors implicated in gene down-regulation and their major identified targets are shown in 
Fig. 9.  The functions of several of these have already been described. In addition, CNOT7 
(hCAF1) is a STAT1-binding negative regulator of Type I and Type II IFN signalling [133], 
while the transcription factor IRF3 is an important responder to PRR activation (Fig. 5) and 
co-operates with NF-κB and IRF7 in the transcription of IRF3- and NF-κB-dependent genes 
[113].  SP1 controls the transcription of multiple genes, many of which have been described 
as promoting the ‘hallmarks’ of cancer: proliferation, independence from growth signals, 
avoidance of apoptosis and immune destruction, invasion and metastasis, and angiogenesis.  
It is overexpressed in many tumors, making it a target for chemotherapy [134, 135].   
Control of up-regulated genes appears to be less integrated with different factors potentially 
regulating small subsets of genes (S8 Table). Furthermore, of the top five listed regulators 
(SMC3, PDLIM2, EBI3, MYOC and NEUROG1, Table 4), little or no expression of EBI3, 
MYOC and NEUROG1 was detected so their significance is hard to determine.  In the case of 
MHC-II genes, SMC3, a subunit of the cohesin protein complex, was identified as a possible 
regulator.  Cohesin co-operates with MHC-II specific transcription factors RFX5 and CIITA 
(up 1.3-fold) to activate MHC-II expression [136].  SMC3 has an ATP-binding domain but 
whether cohesin binding to MHC-II transcriptional insulators could be promoted by Ap4A is 
unknown.  The ubiquitin E3 ligase PDLIM2 (SLIM) is predicted by IPA
®
 to both up-regulate 
and down-regulate different sets of genes (S8 Table).  This prediction appears to be based 
largely on the results of one previous investigation into PDLIM2-modulated gene expression 
in DU145 prostate carcinoma cells [137] and the direction of expression change of about half 
the genes in that study is different from that in ours.  Given that the z-scores for the 
predictions are both below the significance threshold of 2<z<-2, the reliability of this 
prediction is perhaps questionable.  Nevertheless, PDLIM2 suppression is known to alter the 
stability of several of the transcription factor families implicated here in the down-regulated 
responses in NuKO cells including NFκB, IRFs, STATs, JUN and AP-1, and also to promote 
reversal of the EMT phenotype [137].  Although the level of PDLIM2 expression in KBM-7 
cells was not significantly affected by NUDT2 knockout (S2 Table), its activity may have 
been altered as a secondary effect of some other change e.g. to a protein kinase.  Overall, 
though, there is no clear upstream pattern of regulation for the sets of up-regulated genes. 
 
Possible direct targets for Ap4A-mediated gene regulation 
  
While IPA
®
 may have identified potential upstream regulatory factors for some of the 
observed changes in gene expression, the question still remains as to how the elevated level 
of Ap4A impacts on these and other factors to promote these changes.  A number of 
possibilities can be considered. 
 
HINT1 
 
This study was initiated by the suggestion of Razin and co-workers that direct activation of 
MITF and USF2 transcription complexes in mast-related cells occurred by Ap4A-mediated 
displacement of the HINT1 co-repressor.  For example, mast cell protease rMCP-6 (TPSB2), 
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c-Kit (KIT), granzyme B (GZMB) and tryptophan hydroxylase (TPH1) were all up-regulated 
in RBL cells either after direct introduction of Ap4A, after activation by IgE and antigen, or 
after increasing Ap4A by siRNA knockdown of NUDT2 [10, 31].  However, IPA
®
 did not 
identify MITF (up 1.7-fold), USF2 or HINT1 (down 1.3-fold) as potential regulators in our 
study. Furthermore, TPSB2 was up 3.2-fold but KIT was down 2.3-fold and TPH1 unaffected 
(S2 and S3 Tables).  No data were retrieved for GZMB.  The USF2-responsive genes TGFB2, 
SHP (NR0B2), TERT and TSP-1 (THBS1) were also shown to be up-regulated by Ap4A in 
RBL cells [36].  In our study, USF2 expression was unchanged by NUDT2 knockout as was 
the very low-level expression of TGFB2, TERT and THBS1 (S2 Table).  No data were 
obtained for NR0B2.  Elevated Ap4A was also found to activate the MITF-dependent 
transcription of myosin light chain 1a (MYL4) in cardiomyocytes [10], but this gene is not 
expressed in KBM-7 cells.  From a list of 113 genes shown to be up-regulated by MITF in 
melanoma [138], 23 were up- and 20 down-regulated in NuKO cells, which would suggest 
that Ap4A-mediated MITF or USF2 activation is not prominent in our data. 
 
Other genes repressed by HINT1 through its interaction with MITF, USF2 or the WNT/β-
catenin complex include cyclin D1 (CCND1), BCL2, BIRC5, MET, MYC, FRA1, TGFB, 
HIF1A, PAI-1 (SERPINE1) and AXIN2 [139-141].  Of these, BCL2, MYC and AXIN2 were 
slightly up-regulated 1.3-, 1.3- and 2.4-fold while CCND1 was down-regulated 6.2-fold.  
Loss of HINT1 has also been reported to reduce the expression of p21
WAF1/CIP1
 (CDKN1A), 
GADD45A, GADD153 and TP53INP1 [142] but only the predicted slight reduction in 
CDKN1A expression (1.4-fold) was observed in NuKO cells.  Thus, there is no clear evidence 
to support the relief of HINT1 repression of transcription factors as a cause of Ap4A-
mediated differential gene expression in KBM-7 cells.  
 
Purinoceptors 
 
Some Ap4A-mediated transcriptional changes could also involve externalization of Ap4A into 
the growth medium by exocytosis or from damaged or necrotic cells.  This Ap4A could then 
act through cell-surface purinoceptors to modulate known signaling pathways leading to 
changes in gene expression [143].  All known P2 receptor subtypes except P2X2, P2X3, 
P2X6, P2Y4, P2Y12 and P2Y13 were found to be expressed in KBM-7 cells with P2X1, P2X7 
and P2Y8 showing slight but significant up-regulation (1.3–2.3-fold) in NuKO cells (S2 and 
S3 Tables).  Several of these are known to be activated by Ap4A [144]; however, 
measurement of Ap4A in the cell-free growth medium showed that there was actually less in 
the medium taken from NuKO cells (0.11 ± 0.01 pmol/10
6
 cells, n=3) than in that from 
KBM-7 cells (0.28 ± 0.07 pmol/10
6
 cells, n=3), possibly due to the 5.5-fold up-regulation of 
the cell surface phosphodiesterase ENPP1, which is known to hydrolyze extracellular 
diadenosine polyphosphates [3]. Thus, an increased autocrine signaling effect of Ap4A seems 
unlikely. 
 
Chromatin remodeling 
PARP1 and PARP2 are known to be intimately involved in chromatin (de)condensation and 
epigenetic marking through ADP-ribosylation of histones and chromatin remodeling enzymes 
and via interaction with numerous transcription factors, and this has profound effects on gene 
expression [145].  Ap4A can effectively compete with histones as an ADP-ribose acceptor 
resulting in the synthesis of ADPR-Ap4A species [17, 146, 147] and so an elevated level of 
Ap4A could conceivably regulate, or just interfere with, these processes leading to changes in 
gene regulation.  However, the lack of effect on the expression of the selected gene set 
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studied by qRT-PCR after inhibition of PARP1 and PARP2 would argue against a major role 
for PARPs.  Nevertheless, the expression of a large number of histone gene variants is 
affected by NUDT2 disruption, the majority being down-regulated, while changes in the 
expression of several lysine-specific demethylases (KDMs), histone deactylases (HDACs) 
and DNA (cytosine-5)-methyltransferases (DNMTs), several of which are also ADP-
ribosylation targets, is also evident (S3 Table).  Hence, Ap4A-mediated chromatin 
remodelling by some unknown mechanism could still be considered as a potential source of 
differential gene expression. 
Protein kinases and other ATP-dependent factors 
 
By virtue of its structural similarity to ATP, Ap4A might regulate transcription by inhibition 
of protein kinases, of which there are over 500 in the human genome [148].  Ap4A has been 
shown to inhibit v-Src [26], casein kinase II [27] and protein kinase C [28].  These and many 
other protein kinases, some of which might be particularly sensitive to Ap4A, are known to 
regulate transcription factor activity directly or indirectly and several examples of potential 
targets feature in Figs. 4-6.  In the absence of evidence strongly favoring alternative 
possibilities, protein kinases and other ATP-dependent regulatory factors such as 
phosphoinositide kinases, chaperones and ABC transporters must be regarded as likely 
targets for Ap4A that will require future investigation.  
 
Transcript stability 
 
An alternative mechanism whereby increased Ap4A could have a major effect on the 
transcriptome is through inhibition of RNA binding by the nudix protein NUDT21 (CFIm25, 
CPSF5), the 25 kDa component of the cleavage factor Im complex involved in pre-mRNA 3′-
end processing.  Ap4A binds to the same site as RNA with a Kd of 2.4 µM and so might be 
expected to affect 3′-end processing and the half-lives of certain mRNAs [35, 149].  
Knockdown of NUDT21 in glioblastoma cells results in shortened 3′-UTRs in 1450 
transcripts and an increase in cell proliferation [150].  Of these 1450 transcripts, the steady-
state levels of 928 were significantly increased and 28 were decreased.  However, a 
comparison between the transcripts affected after NUDT21 knockdown in glioblastoma cells 
and those up- and down-regulated in NuKO cells revealed no overlap between the down-
regulated genes and only 1 overlap in the top 250 up-regulated genes.  Therefore, despite the 
differences in cell lines, it seems unlikely that NUDT21 is an important target for the 
increased Ap4A in NuKO cells. 
 
Alternative substrates or effects of NUDT2 disruption 
 
Other in vitro substrates for NUDT2 whose levels might be affected by its loss include Ap5A, 
Ap6A, other homodinucleoside polyphosphates with four or more phosphoryl groups, e.g. 
diguanosine tetraphosphate (Gp4G) [4, 5], inorganic polyphosphate [151] and phosphoribosyl 
pyrophosphate [152], but there is no evidence to suggest that these are significant substrates 
in vivo [4].  Ap5A and Ap6A appear to be confined to secretory granules in certain specialized 
cells while no specific mechanisms are known for the synthesis of Gp4G and other 
homodinucleoside polyphosphates in mammalian cells [4, 5].  Heterodinucleoside 
polyphosphates such as Ap4G and Ap4U can also be synthesized by aminoacyl-tRNA 
synthetases and, if present, would be detected by our luminometric assay and included as part 
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of the ‘Ap4A’ pool, but as no unique functions have been ascribed to these molecules they are 
usually considered under the heading ‘Ap4A’ [4]. 
 
Transcript stability could also be affected if NUDT2 were involved in mRNA decapping.  So 
far, two related nudix family proteins, DCP2 (NUDT20) and NUDT16, have been shown to 
participate in mRNA decapping in vivo [153].  However, a further six nudix proteins, 
including NUDT2, have varying degrees of decapping activity in vitro on both 
monomethylated and unmethylated capped RNAs [154].  Although there is currently no 
evidence supporting NUDT2-mediated decapping in vivo, this possibility cannot be 
discounted. Additionally, by virtue of its structural similarity to caps, elevated Ap4A could 
conceivably inhibit decapping by DCP2 and NUDT16.  In both cases, this would most likely 
lead to prolonged half-lives of mRNA subsets and might therefore contribute to the up-
regulation of certain genes. 
 
Finally, loss of NUDT2 could have consequences through the loss of interaction with any 
binding partner.  NUDT2 may have a significant nuclear location [155, 156] and has been 
documented to bind to the replicative helicase component MCM6 [157]. While this may in 
some way be related to the inhibition of replication initiation by Ap4A [17], it is not clear 
how loss of this interaction would have the profound effect on transcription observed in 
NuKO cells.  NUDT2 has also been reported to bind to unliganded estrogen receptor beta 
(ESR2) in the cytosol [158].  This is interesting given the reported repression of NUDT2 
expression by estradiol [78, 159].  However, no significant expression of ESR2 was detected 
in KBM-7 cells (S2 Table and [38]) and so it seems unlikely that the effects of NUDT2 
disruption involve ESR2-mediated gene expression.  Thus, aside from a theoretical effect of 
NUDT2 loss on mRNA decapping, it seems reasonable to conclude that most of the 
transcriptional effects reported here are caused by an increased level of its major substrate, 
Ap4A.  We did attempt to answer this question directly by expression of the Escherichia coli 
ApaH gene in NuKO cells.  ApaH encodes a symmetrically-cleaving Ap4A hydrolase that it 
structurally unrelated to NUDT2 [160] and in so doing we hoped to reduce Ap4A to normal 
levels in a NUDT2-negative background.  However, ApaH expression proved to be toxic to 
the cells, possibly because ApaH may also have protein phosphatase activity [161]. 
 
 
Discussion 
 
Despite being known since the 1960s, Ap4A has never commanded the attention that has been 
bestowed on other low-molecular-weight regulators such as cyclic nucleotides and inositol 
phosphates.  Two competing schools of thought have arisen, one suggesting that Ap4A is a 
physiologically important regulator whose level is finely tuned by the NUDT2 Ap4A 
hydrolase, and the other that it is an unavoidable, non-functional by-product of several 
enzyme activities and that NUDT2 exists simply to eliminate it, lest it cause molecular 
mayhem by interfering with essential, adenine nucleotide-dependent metabolic and 
regulatory pathways [4].  The data presented here clearly demonstrate that increases in 
intracellular Ap4A by disruption of a single gene lead to significant changes to the 
transcriptional program. While some of the observed changes in gene expression may indeed 
be adventitious due to an unregulated and sustained high level of Ap4A, the specific down-
regulation of gene sets involved in the interferon, inflammatory and innate immune responses 
and in cancer promotion support the view that Ap4A is indeed a biologically relevant 
regulator.  Assuming that Ap4A has more than one intracellular target, it is likely that 
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different gene sets will respond to different levels of Ap4A resulting from the regulation of 
NUDT2 activity, translation or transcription in vivo in response to different factors, and so 
not all the effects observed in NuKO cells will necessarily occur at the same time.  
Identification of these targets and the gene networks under their control is a priority for future 
work. 
 
Taking the positive view that Ap4A is a bona fide regulator, what conclusions can be drawn 
about its principal intracellular role(s)?  Rapid suppression of interferon responses after 
activation of the initial signal transduction pathways is an essential part of the overall 
immune response to pathogens to avoid the potential toxicity of the many anti-viral, pro-
apoptotic, and anti-proliferative proteins that are induced.  Therefore, the NuKO phenotype 
may reflect the activation of these feedback mechanisms.  Alternatively, components from 
infecting pathogens such as proteins or 5′-ppp RNAs may actively cause the increased 
intracellular Ap4A by inhibiting NUDT2 in order to down-regulate the immune responses.  
Poliovirus infection is known to cause a slight (2-fold) increase in Ap4A [162] while the 
SARS coronavirus protein 7a physically interacts with NUDT2, although the effect of this on 
the level of Ap4A is not known [163].  Recently, it has been shown that the viral-induced 
mediator of the interferon response, cyclic GAMP, can be transferred from cell to cell inside 
newly-formed virions, and it has been speculated that this is a protective, host-regulated 
mechanism to rapidly establish an antiviral state in newly infected cells [164, 165].  It is 
equally interesting to speculate that viruses may also package Ap4A into new virions to 
counteract this.  With regard to bacterial pathogens, the two types of bacterial Ap4A 
hydrolase, the asymmetrically-cleaving NUDT2 homologue RppH (also known as YgdP or 
IalA) and the unrelated symmetrically-cleaving ApaH, have been classified as invasion 
proteins and are required for optimal survival of bacteria during cellular invasion [166-169]. 
They may help to prevent high host cell Ap4A induced by infection-associated stress from 
inhibiting essential bacterial functions. 
 
The down-regulation of tryptophan catabolism by Ap4A offers a possible explanation as to 
why, of all the aminoacyl-tRNA synthetases able to generate diadenosine oligophosphates, 
mammalian tryptophanyl-tRNA synthetase (WRS) is the only one unable to synthesise Ap4A.  
It can only make Ap3A [170].  WRS is expressed constitutively in all cells, but can be 
strongly induced in many non-lymphoid cells, e.g. monocytes, by Type II interferons, leading 
to a marked increase in Ap3A, but not Ap4A [171, 172].  It has been proposed that this 
induction protects non-lymphoid cells from Trp depletion and the other effects of IDO1 
expression by ensuring that sufficient Trp is diverted into protein synthesis for survival [173].  
Enhanced WRS expression in T cells from patients with several autoimmune disorders is also 
believed to protect them from Trp depletion [72].  If this increased level of WRS were also to 
generate a significant amount of Ap4A, this would compromise the intended 
immunosuppression by down-regulating Trp catabolism. Hence, WRS may have evolved a 
unique inability to make Ap4A.  This also seems to confirm the physiological relevance of 
Ap4A as an important signaling molecule. 
 
Regardless of the mechanisms where by Ap4A exerts its effects and whether these are all 
physiologically relevant, the practical significance of inhibiting NUDT2 is evident.  Our 
results expand upon the earlier demonstration that NUDT2 promotes proliferation of breast 
carcinoma cells and that NUDT2 status could be a useful prognostic marker [78].  The 
potential of NUDT2 as a therapeutic target for cancer simultaneously affecting metastasis, 
invasion, apoptosis, immunosuppression and inflammation certainly warrants further 
investigation and validation in different cancer cells and animal models.  There are currently 
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no known specific small molecule inhibitors of NUDT2; however such molecules have been 
described for the related nudix hydrolase MTH1 [174, 175], suggesting that specific 
inhibition of NUDT2 may be feasible.  It could also be targeted with biotherapeutics.  The 
extent to which the changes in the expression of other genes and pathways brought about by 
NUDT2 disruption might militate against its value as a target will only be determined by 
further investigation.  
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Figure Legends 
 
Fig. 1.  Ion-exchange chromatography of Ap4A extracted from KBM-7-NuKO cells and 
(inset) western blot analysis of cell extracts for the presence of NUDT2 protein.   A 
nucleotide extract from NuKO cells was subjected to ion-exchange chromatography and 
fractions assayed luminometrically for Ap4A as described in Materials and Methods.  Inset: a 
sample of recombinant NUDT2 and protein extracts of KBM-7 and KBM-7 NuKO cells were 
subjected to polyacrylamide gel electrophoresis and subsequent nitrocellulose blots probed 
for the presence of NUDT2 with rabbit polyclonal anti-NUDT2 (Santa Cruz) followed by 
detection with HRP-conjugated goat-anti-rabbit IgG and ECL visualization (ECL Select, GE 
Healthcare).  Mouse β-actin was detected with HRP-conjugated goat-anti-mouse IgG (Santa 
Cruz). 
 
Fig. 2.  Principal component analysis (PCA), correlation analysis and MA plot of 
differential gene expression data. (A) PCA plot of log2 gene expression data showing the 
2
nd 
and 3
rd 
principal components.  (B) Heatmap visualization of the Pearson correlation 
coefficients of log2 gene expression between samples.  The three samples from wild type 
KBM-7 cells are labeled WT1-WT3 and those from the KBM-7-NuKO cells KO1-KO3. (C) 
MA plot showing the distribution of mean gene expression levels (log2Counts Per Million 
mapped reads) against log2 Fold-Change (KO vs WT) for individual gene responses. Low 
expression genes (log2CPM < −5) are colored orange. Significant differentially expressed 
genes (DEGs) are colored red; genes showing no change in expression are colored black.  
 
Fig. 3.  Validation of RNA-Seq data for differential gene expression by qRT-PCR.  qRT-
PCR analysis was performed on selected RNAs from KBM-7 and NuKO cells in the presence 
and absence of 100 nM of the PARP inhibitor KU-0058948 using the primers listed in S1 
Table as described in Materials and Methods and the log2 fold-change in expression plotted 
beside those obtained by RNA-Seq analysis.  Inset: simple correlation plot of the log2 fold-
changes in expression obtained by RNA-Seq (x-axis) and qRT-PCR without PARP inhibitor 
(y-axis). 
 
Fig. 4. Canonical pathway for Type I and Type II interferon signaling via cell surface 
IFNR receptors.  Down-regulated genes are in green, up-regulated genes in red.  Color 
intensity corresponds to the fold change; bold borders highlight genes with >2-fold change in 
expression. Lines correspond to physical interactions and arrows to functional relationships 
between proteins. Solid lines and arrows imply direct relationships and dotted lines and 
arrows imply indirect relationships. Functional relationships include post-translational 
modifications, transcription regulation, proteolysis or co-expression. Flat arrowheads 
indicate inhibition. 
 
Fig. 5. Canonical pathway for the role of RIG-1-like receptors in antiviral innate 
immunity.  Explanation of symbols as in Fig. 4.   
 
Fig. 6. Canonical pathway for transcriptional activation by NFκB Explanation of 
symbols as in Fig. 4.   
 
Fig. 7. Top metabolic canonical pathways associated with down-regulated (black) and 
up-regulated (grey) gene sets.  The dotted line represents the threshold above which there 
are statistically significantly more genes in a pathway than expected by chance (-log(FDR-
 21 
adjusted P-value) >1.3). 
 
Fig. 8.  Growth inhibition curves for cells in the presence of (A) methylmethane 
sulfonate (MMS), (B) N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) and (C) N-
methylnitrosourea (MNU).  Growth of KBM-7 (open symbols) and KBM-7-NuKO (closed 
symbols) cells was assessed as described in Materials and Methods.                                                                                                                         
 
Fig. 9. The top-ranked upstream transcription factors (in centre) suggested by IPA
®
 for 
the set of down-regulated genes (outer circle). The top two-ranked cytokines, IFNA2 and 
IFNL1 are also included.  Genes with >1.2 fold down-regulation are in green; those with 
>1.2-fold up-regulation are in red. Color intensity corresponds to the fold change. Genes 
corresponding to immediate downstream targets of IRFs are enlarged with blue borders and 
connections. 
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observed overall direction of regulation [down (-) or up(+)], -log2(P-value), z-score and key 
molecules in each pathway.                                                                                             (XSLX) 
 
S5 Table.  DEGs from this study previously shown to be regulated by (A) Type I, (B) 
Type II and/or (C) Type III interferons according to the Interferome v2.01 database.  
Data include Ensembl id, gene id and description, and fold up- (red) or down- (green) 
regulation in this study.  Genes potentially showing specific regulation by Type III IFNs are 
highlighted in yellow.                                                                                                      (XSLX) 
S6 Table.  Genes identified by IPA
®
 to be associated with rheumatoid arthritis and 
systemic lupus erythematosus.                                                                                     (XSLX) 
S7 Table.  Top 40 down- and top 40 up-regulated genes with P ≤ 0.05 and FPKM >0.3 
and their association with cancer.                                                                                (XSLX) 
S8 Table.  Upstream regulators predicted by IPA
®
.  Data include the predicted upstream 
regulator, the direction of regulation with which it is associated (- down; + up), the type of 
molecule, the activation state (predicted direction of the biological function), the activation z-
score, where >2.0 or <-2.0 is significantly predictive, the P-value and the molecules for 
which there is documented evidence for regulation.  The top transcription factors examined in 
Fig. 9 are highlighted in green.                                                                                       (XSLX) 
 
